Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma

Kuninori Otsuka, Yorihisa Imanishi, Noboru Habu, Yoichiro Sato, Seiji Shigetomi, Ryoichi Fujii, Koji Sakamoto, Toshiki Tomita, Masato Fujii, Kaori Kameyama, Kaoru Ogawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Because of its low incidence, the clinical characteristics of the salivary duct carcinoma (SDC) based on a statistical analysis with a large number of patients remain to be elucidated, and thus it has been impossible to standardize the optimal treatments of SDC including adjuvant systemic therapy. Aims: The present study aimed to determine the prognostic factors along with the clinical outcomes of patients with SDC and to evaluate the expression of several receptor molecules as treatment targets. Methods: We performed a statistical analysis and immunohistochemical examination of 16 patients with SDC who had undergone initial treatment in the Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine from 1996 to 2010. Results: The 3-year disease-free survival (DFS) and cause-specific survival (CSS) rates were 29.2% and 72.7%, respectively. At the time of the analysis, 6 patients are alive without the disease, 2 patients are alive with distant metastasis, whereas 7 patients had died of distant metastasis, and 1 patient had died of another cause (pulmonary embolism). We examined the prognostic value of the clinico-pathological factors such as age, sex, T classification, N classification, clinical stage, primary site, histological pre-existence of pleomorphic adenoma. A univariate analysis revealed that DFS was significantly correlated with age (p = 0.049), T classification (p = 0.018), and clinical stage (p = 0.029), whereas no factor was found to be correlated with CSS. A multivariate analysis demonstrated that age (≥61 vs. ≤60, risk ratio (RR) = 5.423, p = 0.042) and T classification (3, 4 vs. 1, 2, RR= 1.087, p = 0.020) were the independent prognostic factors for DFS. Positive expressions of HER2, ER (estrogen receptor), PR (progesterone receptor), AR (androgen receptor), and MIB-1 (index<20%) were found in 50%, 6%, 13%, 100%, and 69%, respectively. However, none of them showed significant correlation with survival. Conclusion: Frequent expressions of HER-2 and AR in SDC suggest that these receptors can be suitable molecular targets of systemic therapy for patients with SDC in which distant metastasis seems to be the largest obstacle to improving survival. In order to assess the efficacy of anti-HER-2 therapy and anti-androgen therapy for each receptor-positive SDC, a multi-institutional joint research system should be organized.

Original languageEnglish
Pages (from-to)1024-1032
Number of pages9
JournalJournal of Otolaryngology of Japan
Volume116
Issue number9
DOIs
Publication statusPublished - 2013 Sep

Fingerprint

Salivary Ducts
Androgen Receptors
Survival Analysis
Carcinoma
Disease-Free Survival
Neoplasm Metastasis
Therapeutics
Survival
Odds Ratio
Pleomorphic Adenoma
Otolaryngology
Progesterone Receptors
Pulmonary Embolism
Estrogen Receptors
Androgens
Neck
Multivariate Analysis
Survival Rate
Head
Medicine

Keywords

  • AR (androgen receptor)
  • Clinical statistics
  • HER-2
  • Prognostic factor
  • Salivary duct carcinoma

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma. / Otsuka, Kuninori; Imanishi, Yorihisa; Habu, Noboru; Sato, Yoichiro; Shigetomi, Seiji; Fujii, Ryoichi; Sakamoto, Koji; Tomita, Toshiki; Fujii, Masato; Kameyama, Kaori; Ogawa, Kaoru.

In: Journal of Otolaryngology of Japan, Vol. 116, No. 9, 09.2013, p. 1024-1032.

Research output: Contribution to journalArticle

Otsuka, Kuninori ; Imanishi, Yorihisa ; Habu, Noboru ; Sato, Yoichiro ; Shigetomi, Seiji ; Fujii, Ryoichi ; Sakamoto, Koji ; Tomita, Toshiki ; Fujii, Masato ; Kameyama, Kaori ; Ogawa, Kaoru. / Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma. In: Journal of Otolaryngology of Japan. 2013 ; Vol. 116, No. 9. pp. 1024-1032.
@article{e38de84a230a43629f7e872b7ff985bf,
title = "Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma",
abstract = "Background: Because of its low incidence, the clinical characteristics of the salivary duct carcinoma (SDC) based on a statistical analysis with a large number of patients remain to be elucidated, and thus it has been impossible to standardize the optimal treatments of SDC including adjuvant systemic therapy. Aims: The present study aimed to determine the prognostic factors along with the clinical outcomes of patients with SDC and to evaluate the expression of several receptor molecules as treatment targets. Methods: We performed a statistical analysis and immunohistochemical examination of 16 patients with SDC who had undergone initial treatment in the Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine from 1996 to 2010. Results: The 3-year disease-free survival (DFS) and cause-specific survival (CSS) rates were 29.2{\%} and 72.7{\%}, respectively. At the time of the analysis, 6 patients are alive without the disease, 2 patients are alive with distant metastasis, whereas 7 patients had died of distant metastasis, and 1 patient had died of another cause (pulmonary embolism). We examined the prognostic value of the clinico-pathological factors such as age, sex, T classification, N classification, clinical stage, primary site, histological pre-existence of pleomorphic adenoma. A univariate analysis revealed that DFS was significantly correlated with age (p = 0.049), T classification (p = 0.018), and clinical stage (p = 0.029), whereas no factor was found to be correlated with CSS. A multivariate analysis demonstrated that age (≥61 vs. ≤60, risk ratio (RR) = 5.423, p = 0.042) and T classification (3, 4 vs. 1, 2, RR= 1.087, p = 0.020) were the independent prognostic factors for DFS. Positive expressions of HER2, ER (estrogen receptor), PR (progesterone receptor), AR (androgen receptor), and MIB-1 (index<20{\%}) were found in 50{\%}, 6{\%}, 13{\%}, 100{\%}, and 69{\%}, respectively. However, none of them showed significant correlation with survival. Conclusion: Frequent expressions of HER-2 and AR in SDC suggest that these receptors can be suitable molecular targets of systemic therapy for patients with SDC in which distant metastasis seems to be the largest obstacle to improving survival. In order to assess the efficacy of anti-HER-2 therapy and anti-androgen therapy for each receptor-positive SDC, a multi-institutional joint research system should be organized.",
keywords = "AR (androgen receptor), Clinical statistics, HER-2, Prognostic factor, Salivary duct carcinoma",
author = "Kuninori Otsuka and Yorihisa Imanishi and Noboru Habu and Yoichiro Sato and Seiji Shigetomi and Ryoichi Fujii and Koji Sakamoto and Toshiki Tomita and Masato Fujii and Kaori Kameyama and Kaoru Ogawa",
year = "2013",
month = "9",
doi = "10.3950/jibiinkoka.116.1024",
language = "English",
volume = "116",
pages = "1024--1032",
journal = "Journal of Otolaryngology of Japan",
issn = "0030-6622",
publisher = "Oto-Rhino-Laryngological Society of Japan Inc.",
number = "9",

}

TY - JOUR

T1 - Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma

AU - Otsuka, Kuninori

AU - Imanishi, Yorihisa

AU - Habu, Noboru

AU - Sato, Yoichiro

AU - Shigetomi, Seiji

AU - Fujii, Ryoichi

AU - Sakamoto, Koji

AU - Tomita, Toshiki

AU - Fujii, Masato

AU - Kameyama, Kaori

AU - Ogawa, Kaoru

PY - 2013/9

Y1 - 2013/9

N2 - Background: Because of its low incidence, the clinical characteristics of the salivary duct carcinoma (SDC) based on a statistical analysis with a large number of patients remain to be elucidated, and thus it has been impossible to standardize the optimal treatments of SDC including adjuvant systemic therapy. Aims: The present study aimed to determine the prognostic factors along with the clinical outcomes of patients with SDC and to evaluate the expression of several receptor molecules as treatment targets. Methods: We performed a statistical analysis and immunohistochemical examination of 16 patients with SDC who had undergone initial treatment in the Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine from 1996 to 2010. Results: The 3-year disease-free survival (DFS) and cause-specific survival (CSS) rates were 29.2% and 72.7%, respectively. At the time of the analysis, 6 patients are alive without the disease, 2 patients are alive with distant metastasis, whereas 7 patients had died of distant metastasis, and 1 patient had died of another cause (pulmonary embolism). We examined the prognostic value of the clinico-pathological factors such as age, sex, T classification, N classification, clinical stage, primary site, histological pre-existence of pleomorphic adenoma. A univariate analysis revealed that DFS was significantly correlated with age (p = 0.049), T classification (p = 0.018), and clinical stage (p = 0.029), whereas no factor was found to be correlated with CSS. A multivariate analysis demonstrated that age (≥61 vs. ≤60, risk ratio (RR) = 5.423, p = 0.042) and T classification (3, 4 vs. 1, 2, RR= 1.087, p = 0.020) were the independent prognostic factors for DFS. Positive expressions of HER2, ER (estrogen receptor), PR (progesterone receptor), AR (androgen receptor), and MIB-1 (index<20%) were found in 50%, 6%, 13%, 100%, and 69%, respectively. However, none of them showed significant correlation with survival. Conclusion: Frequent expressions of HER-2 and AR in SDC suggest that these receptors can be suitable molecular targets of systemic therapy for patients with SDC in which distant metastasis seems to be the largest obstacle to improving survival. In order to assess the efficacy of anti-HER-2 therapy and anti-androgen therapy for each receptor-positive SDC, a multi-institutional joint research system should be organized.

AB - Background: Because of its low incidence, the clinical characteristics of the salivary duct carcinoma (SDC) based on a statistical analysis with a large number of patients remain to be elucidated, and thus it has been impossible to standardize the optimal treatments of SDC including adjuvant systemic therapy. Aims: The present study aimed to determine the prognostic factors along with the clinical outcomes of patients with SDC and to evaluate the expression of several receptor molecules as treatment targets. Methods: We performed a statistical analysis and immunohistochemical examination of 16 patients with SDC who had undergone initial treatment in the Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine from 1996 to 2010. Results: The 3-year disease-free survival (DFS) and cause-specific survival (CSS) rates were 29.2% and 72.7%, respectively. At the time of the analysis, 6 patients are alive without the disease, 2 patients are alive with distant metastasis, whereas 7 patients had died of distant metastasis, and 1 patient had died of another cause (pulmonary embolism). We examined the prognostic value of the clinico-pathological factors such as age, sex, T classification, N classification, clinical stage, primary site, histological pre-existence of pleomorphic adenoma. A univariate analysis revealed that DFS was significantly correlated with age (p = 0.049), T classification (p = 0.018), and clinical stage (p = 0.029), whereas no factor was found to be correlated with CSS. A multivariate analysis demonstrated that age (≥61 vs. ≤60, risk ratio (RR) = 5.423, p = 0.042) and T classification (3, 4 vs. 1, 2, RR= 1.087, p = 0.020) were the independent prognostic factors for DFS. Positive expressions of HER2, ER (estrogen receptor), PR (progesterone receptor), AR (androgen receptor), and MIB-1 (index<20%) were found in 50%, 6%, 13%, 100%, and 69%, respectively. However, none of them showed significant correlation with survival. Conclusion: Frequent expressions of HER-2 and AR in SDC suggest that these receptors can be suitable molecular targets of systemic therapy for patients with SDC in which distant metastasis seems to be the largest obstacle to improving survival. In order to assess the efficacy of anti-HER-2 therapy and anti-androgen therapy for each receptor-positive SDC, a multi-institutional joint research system should be organized.

KW - AR (androgen receptor)

KW - Clinical statistics

KW - HER-2

KW - Prognostic factor

KW - Salivary duct carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84886560928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886560928&partnerID=8YFLogxK

U2 - 10.3950/jibiinkoka.116.1024

DO - 10.3950/jibiinkoka.116.1024

M3 - Article

C2 - 24191589

AN - SCOPUS:84886560928

VL - 116

SP - 1024

EP - 1032

JO - Journal of Otolaryngology of Japan

JF - Journal of Otolaryngology of Japan

SN - 0030-6622

IS - 9

ER -